OvaScience: Reproducible Results (NASDAQ:OVAS-OLD)

[frothmouth]

“ The stock is at a bargain price for those who missed the first round of appreciation. The stock offers a 100% upside based on the recent high and in fact a higher upside as the company ramps up AUGMENT treatment.”